OCUL Ocular Therapeutix Inc.

4.16
+0.55  (+15%)
Previous Close 3.61
Open 3.87
Price To Book 3.75
Market Cap 170956748
Shares 41,095,372
Volume 2,204,185
Short Ratio
Av. Daily Volume 469,593

NewsSee all news

  1. Watch These Four Biotech Stocks Friday
  2. Ocular Therapeutix™ Prices $37.5 Million Subordinated Convertible Debt Financing
  3. Ocular Therapeutix™ Announces Dosing of First Patient in OTX-TKI (tyrosine kinase inhibitor implant) Phase 1 Clinical Trial for the Treatment of Wet Age-related Macular Degeneration (AMD)
  4. Is Ocular Therapeutix, Inc. (NASDAQ:OCUL) A Financially Sound Company?
  5. Detailed Research: Economic Perspectives on Inovalon, Merit Medical, Senseonics, Ocular Therapeutix, The Hartford Financial Services Group, and Synopsys — What Drives Growth in Today's Competitive Landscape

SEC filingsSee all SEC filings

  1. 8-K - Current report 19623970
  2. 8-K - Current report 19617162
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19607309
  4. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19594994
  5. EFFECT - Notice of Effectiveness 19593103

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

sNDA filing announced January 10, 2019.
DEXTENZA
Post-surgical ocular inflammation and pain
Phase 3 trial did not meet primary endpoint - June 2016. Additional Phase 3 trial to be initiated pending data from a non-significant risk device study to be initiated in 2017.
DEXTENZA
Allergic conjunctivitis
Phase 3 data due 1H 2019.
OTX-TP
Glaucoma and ocular hypertension
FDA approval announced December 3, 2018.
DEXTENZA
Ocular inflammation and pain following cataract surgery
Phase 2 complete. Assessing plans forward.
DEXTENZA
Dry Eye Disease
Phase 1 data due 1H 2019.
OTX-TIC
Glaucoma and ocular hypertension
Phase 1 dosing of first patient announced February 20, 2019.
OTX-TKI
Wet Age-related Macular Degeneration (AMD)

Latest News

  1. Watch These Four Biotech Stocks Friday
  2. Ocular Therapeutix™ Prices $37.5 Million Subordinated Convertible Debt Financing
  3. Ocular Therapeutix™ Announces Dosing of First Patient in OTX-TKI (tyrosine kinase inhibitor implant) Phase 1 Clinical Trial for the Treatment of Wet Age-related Macular Degeneration (AMD)
  4. Is Ocular Therapeutix, Inc. (NASDAQ:OCUL) A Financially Sound Company?
  5. Detailed Research: Economic Perspectives on Inovalon, Merit Medical, Senseonics, Ocular Therapeutix, The Hartford Financial Services Group, and Synopsys — What Drives Growth in Today's Competitive Landscape
  6. Ocular (OCUL) Submits an sNDA for Eye Pain Drug Dextenza
  7. The Daily Biotech Pulse: Agile Gives Regulatory Update On Contraceptive Patch, Advaxis Misses Estimates, Ocular Submits sNDA
  8. Ocular Therapeutix™ Submits Supplemental New Drug Application (sNDA) for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Inflammation Following Ophthalmic Surgery
  9. Purdue Pharma L.P. and Ocular Therapeutix, Inc. Announce Initiation of Collaborative Research Activities to Evaluate Innovative Formulations for Non-Opioid Treatments for Pain
  10. Ocular Therapeutix™ Announces Completion of Debt Refinancing
  11. Edited Transcript of OCUL earnings conference call or presentation 7-Nov-18 9:30pm GMT
  12. Are Insiders Buying Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stock?
  13. Ocular Therapeutix™ Added to Nasdaq Biotechnology Index
  14. Ocular Therapeutix™ Announces the Hiring of Chad Brines, Vice President, Sales
  15. Options Traders Expect Huge Moves in Ocular Therapeutix (OCUL) Stock
  16. CORRECTING and REPLACING Ocular Therapeutix™ Announces FDA Approval of DEXTENZA® for the Treatment of Ocular Pain Following Ophthalmic Surgery
  17. Ocular Therapeutix™ to Present at the 30th Annual Piper Jaffray Healthcare Conference
  18. H.C. Wainwright Sees over 80% Upside Potential for These Three Biotech Stocks
  19. Recent Analysis Shows Clovis Oncology, Evertec, Etsy, Ring Energy, Ocular Therapeutix, and Destination Maternity Market Influences — Renewed Outlook, Key Drivers of Growth
  20. Ocular Therapeutix (OCUL) Reports Q3 Loss, Tops Revenue Estimates

SEC Filings

  1. 8-K - Current report 19623970
  2. 8-K - Current report 19617162
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19607309
  4. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19594994
  5. EFFECT - Notice of Effectiveness 19593103
  6. SC 13G - Statement of acquisition of beneficial ownership by individuals 19576660
  7. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19573565
  8. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19558695
  9. DEL AM - Delaying amendment 19528274
  10. S-3 - Registration statement under Securities Act of 1933 181257554